Copyright
©The Author(s) 2018.
World J Gastroenterol. Mar 28, 2018; 24(12): 1321-1331
Published online Mar 28, 2018. doi: 10.3748/wjg.v24.i12.1321
Published online Mar 28, 2018. doi: 10.3748/wjg.v24.i12.1321
Variable | Hazard ratio for recurrence | Hazard ratio for death | ||
HR (95%CI) | P value | HR (95%CI) | P value | |
MELD score (per point) | 1.03 (0.98-1.09) | 0.26 | 1.05 (1.003-1.09) | 0.04a |
Diameter of the largest tumor at time of transplant (per cm) | 1.27 (1.04-1.56) | 0.02a | 1.21 (1.03-1.41) | 0.02 |
Tumor number at time of transplant | 1.001 (0.73-1.37) | 1.00 | 0.93 (0.72-1.20) | 0.57 |
Neutrophil lymphocyte ratio > 4 | 2.24 (1.17-4.26) | 0.02a | 1.66 (1.004-2.73) | 0.048a |
Hypothyroidism | 1.26 (0.55-2.85) | 0.59 | 1.54 (0.82-2.90) | 0.18 |
BALAD components | ||||
Albumin (per g/dL) | 0.75 (0.41-1.38) | 0.36 | 0.69 (0.43-1.13) | 0.14 |
Bilirubin (per mg/dL) | 1.03 (0.98-1.09) | 0.21 | 1.04 (0.995-1.08) | 0.08 |
AFP: > 400 ng/mL | 2.42 (1.18-5.00) | 0.02a | 3.27 (1.84-5.80) | < 0.001b |
AFP-L3 > 15% | 1.86 (0.98-3.52) | 0.056 | 1.88 (1.14-3.09) | 0.01a |
DCP > 1.2 ng/mL | 2.83 (1.42-5.61) | 0.003b | 2.40 (1.43-4.04) | < 0001b |
BALAD Score | ||||
0 | Reference | Reference | ||
1 | 0.70 (0.20-2.47) | 0.58 | 1.14 (0.40-3.23) | 0.81 |
2 | 1.18 (0.37-3.75) | 0.78 | 2.01 (0.75-5.38) | 0.17 |
3 | 1.99 (0.62-6.36) | 0.24 | 2.73 (0.99-7.51) | 0.052 |
4 | 2.97 (0.84-10.58) | 0.09 | 4.68 (1.52-14.36) | 0.007b |
5 | 5.02 (0.92-27.54) | 0.06 | 17.40 (3.81-79.47) | < 0.001b |
BALAD Score (per increase of 1) | 1.48 (1.15-1.91) | 0.002b | 1.59 (1.28-1.97) | < 0.001b |
BALAD-2 Score | ||||
1 | Reference | Reference | ||
2 | 0.41 (0.12-1.32) | 0.13 | 1.07 (0.50-2.28) | 0.86 |
3 | 1.53 (0.66-3.54) | 0.32 | 1.76 (0.87-3.54) | 0.11 |
4 | 2.17 (0.90-5.25) | 0.09 | 2.45 (1.16-5.17) | 0.02a |
BALAD-2 Score (per increase of 1) | 1.45 (1.06-1.98) | 0.02a | 1.38 (1.09-1.76) | 0.008b |
Within Milan criteria at diagnosis | 1.69 (0.84-3.41) | 0.14 | 2.17 (1.25-3.78) | 0.006b |
Within UCSF criteria at diagnosis | 1.85 (0.85-4.05) | 0.12 | 3.19 (1.75-5.84) | < 0.001b |
Within Milan criteria at transplant | 1.24 (0.59-2.62) | 0.57 | 1.06 (0.57-1.95) | 0.86 |
Within UCSF criteria at transplant | 0.33 (0.05-2.43) | 0.28 | 0.68 (0.21-2.17) | 0.51 |
z-GALAD | 1.12 (1.03-1.21) | 0.006b | 1.12 (1.06-1.19) | < 0.001b |
GALAD score | 3.01 (1.14-7.91) | 0.03a | 3.22 (1.48-7.00) | 0.003b |
AFP model cutoff > 2 (explant) | 2.82 (1.47-5.41) | 0.002b | 2.83 (1.67-4.82) | < 0.001b |
AFP model (per increase of 1, explant) | 1.42 (1.20-1.68) | < 0.001b | 1.34 (1.16-1.54) | < 0.001b |
- Citation: Wongjarupong N, Negron-Ocasio GM, Chaiteerakij R, Addissie BD, Mohamed EA, Mara KC, Harmsen WS, Theobald JP, Peters BE, Balsanek JG, Ward MM, Giama NH, Venkatesh SK, Harnois DM, Charlton MR, Yamada H, Algeciras-Schimnich A, Snyder MR, Therneau TM, Roberts LR. Model combining pre-transplant tumor biomarkers and tumor size shows more utility in predicting hepatocellular carcinoma recurrence and survival than the BALAD models. World J Gastroenterol 2018; 24(12): 1321-1331
- URL: https://www.wjgnet.com/1007-9327/full/v24/i12/1321.htm
- DOI: https://dx.doi.org/10.3748/wjg.v24.i12.1321